American Journal of Therapeutics. .
(Obviously just another quack outfit!)
Conclusions:
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Many rigorously controlled, peer-reviewed studies and clinical trials have failed to find a positive result for ivermectin for treating Covid. The results of these studies have been reported in the most prestigious Journals here and abroad such as The Lancet, JAMA, NEJM and the Journal of Clinical Infectious Diseases, among others. Their conclusions are the same -- that it is not a viable option to treat Covid 19 patients.
In general, most of the ivermectin studies that claim a positive benefit are considered low quality and often with potential sources of bias.
It's only the smaller, lower quality trials that have been positive. It may sound impressive to use the American Journal of Therapeutics as a source, but this publication is NOT held in esteem by the scientific community. In fact, it is listed among representatives of "Opportunistic journals" in Clinical Pharmacology. "Predatory journal" is the customary term for these where profit is made through businesses founded to fill a need for a product or service. Many of these journals accept for publication manuscripts with little or no peer review or even outright falsification of data.
Yet, headlines from this publication have gone viral as "evidence" that these findings are more significant than numerous comprehensive well designed studies which have opposite findings. Misinformation abounds.